BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rinvoq (upadacitinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rinvoq (upadacitinib)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06389136-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06389136)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Atopic Dermatitis.\nStudy: A 
 Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic
  Dermatitis and Inadequate Response to Dupilumab\nEstimated primary comple
 tion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 upadacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06389136
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843693-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rinvoq (upadacitinib): Phase 1 readout est. (NCT07843693)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 1.\nStudy: A Study to Evaluate th
 e Safety and Pharmacokinetics of Multiple Doses Upadacitinib\, Tofacitinib
 \, and Baricitinib in Healthy Adult Volunteers\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/up
 adacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07843693
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928272-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06928272)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3.\nStudy: Long Covid (LC)-REVITA
 LIZE - A Long Covid Repurposed Drug Study\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upadaci
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06928272
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06862284-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Rinvoq (upadacitinib): Phase 2 readout est. (NCT06862284)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 2.\nStudy: Therapeutic Effect of 
 Upadacitinib in Primary Sjögren's Syndrome\nEstimated primary completion:
  30 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/up
 adacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06862284
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07149467-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT07149467)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: Uste
 kinumab and Upadacitinib for Induction and Maintenance Therapy in Patients
  With Refractory Crohn's Disease: A Multicenter\, Randomized\, Parallel-Co
 ntrolled Study\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07149467
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06520397-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT06520397)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4\, Crohn's Disease.\nStudy: Effi
 cacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab
  Versus Intensified Ustekinumab Therapy in Crohn's Disease\nEstimated prim
 ary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06520397
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06701331-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06701331)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Atopic Dermatitis.\nStudy: Sa
 fety and Efficacy of Upadacitinib in Combination With Topical Corticostero
 ids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate
  to Severe Atopic Dermatitis\nEstimated primary completion: January 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06701331
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05843643-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT05843643)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Systemic Lupus Erythematosus.
 \nStudy: Program to Assess Adverse Events and Change in Disease Activity o
 f Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic
  Lupus Erythematosus\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05843643
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636057-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20270305
DTEND;VALUE=DATE:20270306
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT07636057)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4\, Rheumatoid Arthritis.\nStudy:
  Comparison of Effectiveness and Safety of Tofacitinib Versus Upadacitinib
  as Add-on to Methotrexate in Rheumatoid Arthritis\nEstimated primary comp
 letion: 5 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /upadacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07636057
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07546097-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT07546097)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4\, Ulcerative Colitis.\nStudy: C
 omparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line 
 Therapy for Acute Severe Ulcerative Colitis（UPFRONT）\nEstimated primar
 y completion: 30 March 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/upadacitinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07546097
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660693-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06660693)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: C
 omparison of Medical RESCUE Strategies for Patients With Steroid-refractor
 y Acute Severe Ulcerative Colitis\nEstimated primary completion: May 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06660693
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018206-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT07018206)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4.\nStudy: Impact Of Upadacitinib
  On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axi
 al Spondyloarthritis\nEstimated primary completion: May 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07018206
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06684522-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rinvoq (upadacitinib): Phase 1 readout est. (NCT06684522)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 1.\nStudy: Upadacitinib as a Nove
 l Treatment for Refractory Eyelid Dermatitis\nEstimated primary completion
 : June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upadacit
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06684522
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06227910-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06227910)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Di
 sease\nEstimated primary completion: 8 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06227910
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03006068-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT03006068)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-
 494) in Participants With Ulcerative Colitis (UC)\nEstimated primary compl
 etion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upa
 dacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03006068
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07727889-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Rinvoq (upadacitinib): Phase 2 readout est. (NCT07727889)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 2\, Hidradenitis Suppurativa.\nSt
 udy: A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidr
 adenitis Suppurativa\nEstimated primary completion: 1 July 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07727889
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07064889-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Rinvoq (upadacitinib): Phase 2 readout est. (NCT07064889)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 2.\nStudy: The Combination of Upa
 dacitinib and High-dose Dexamethasone as First-line Treatment in Adult Imm
 une Thrombocytopenia\nEstimated primary completion: 30 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07064889
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03345823-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT03345823)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: A Ma
 intenance and Long-Term Extension Study of the Efficacy and Safety of Upad
 acitinib (ABT-494) in Participants With Crohn's Disease Who Completed the 
 Studies M14-431 or M14-433\nEstimated primary completion: September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03345823
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867329-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT05867329)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4\, Ulcerative Colitis.\nStudy: F
 easibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) f
 or Acute Severe Ulcerative Colitis\nEstimated primary completion: November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05867
 329
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678645-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rinvoq (upadacitinib): Phase 2 readout est. (NCT07678645)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 2\, Atopic Dermatitis.\nStudy: Th
 e Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cho
 langitis and Atopic Dermatitis With Moderate to Severe Itching\nEstimated 
 primary completion: 30 November 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07678645
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07773623-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT07773623)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4.\nStudy: An Interventional Stud
 y of Upadacitinib Extended-Release Tablets in Patients With Refractory Uve
 itis\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07773623
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Rinvoq (upadacitinib): Phase 2 readout est. (NCT07138898)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 2.\nStudy: Immunosuppressant Mana
 gement in Rheumatology Patients Undergoing Elective Total Shoulder Arthrop
 lasty\nEstimated primary completion: January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118411-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06118411)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Vitiligo.\nStudy: A Study To 
 Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Ad
 ult and Adolescent Participants With Vitiligo\nEstimated primary completio
 n: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upadac
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06118411
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550673-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT07550673)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4\, Ulcerative Colitis.\nStudy: U
 padacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ul
 cerative Colitis（UPRISE）\nEstimated primary completion: 1 April 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07550673
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492251-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Rinvoq (upadacitinib): Phase 2 readout est. (NCT07492251)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 2.\nStudy: Upadacitinib in Adult 
 Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Pro
 spective Multicenter Randomized Placebo-controlled Study.\nEstimated prima
 ry completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/upadacitinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07492251
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670156-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rinvoq (upadacitinib): Phase 1/2 readout est. (NCT07670156)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 1/2.\nStudy: Upadacitinib in Trea
 tment of JAK/STAT Pathway Disorders With Activating Mutations\nEstimated p
 rimary completion: August 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07670156
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04161898-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT04161898)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3.\nStudy: A Study to Evaluate th
 e Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteri
 tis (TAK)\nEstimated primary completion: August 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04161898
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05782907-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT05782907)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: S
 tudy to Assess Adverse Events\, Change in Disease Activity\, and How Oral 
 Upadacitinib Moves Through the Body of Pediatric Participants With Moderat
 ely to Severely Active Ulcerative Colitis.\nEstimated primary completion: 
 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upadacit
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05782907
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05889182-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT05889182)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Hidradenitis Suppurativa.\nSt
 udy: A Study to Assess Change in Disease Activity and Adverse Events of Or
 al Upadacitinib in Adult and Adolescent Participants With Moderate to Seve
 re Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy\nEstimated pr
 imary completion: August 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/upadacitinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05889182
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06454188-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT06454188)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4\, Psoriatic Arthritis.\nStudy: 
 A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcom
 es in Patients With Active Psoriatic Arthritis\nEstimated primary completi
 on: September 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/u
 padacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06454188
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770646-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT07770646)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4.\nStudy: A Pragmatic Trial of I
 nterleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necros
 is Factor-alpha Inhibitor Failure in Axial Spondyloarthritis\nEstimated pr
 imary completion: 15 September 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07770646
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03725007-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rinvoq (upadacitinib): Phase 1 readout est. (NCT03725007)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 1.\nStudy: A Study to Evaluate th
 e Pharmacokinetics\, Safety\, and Tolerability of Upadacitinib in Pediatri
 c Subjects With Polyarticular Course Juvenile Idiopathic Arthritis\nEstima
 ted primary completion: December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03725007
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502339-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT07502339)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4\, Ulcerative Colitis.\nStudy: U
 padacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis\
 nEstimated primary completion: 1 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07502339
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07510191-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT07510191)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4\, Crohn's Disease.\nStudy: TNFi
  Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease Wit
 h Suboptimal Response\nEstimated primary completion: 31 December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07510191
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023302-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT07023302)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Alopecia Areata.\nStudy: A St
 udy to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Ad
 ult and Adolescent Participants in Japan With Alopecia Areata\nEstimated p
 rimary completion: February 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07023302
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06687551-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT06687551)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4\, Rheumatoid Arthritis.\nStudy:
  JAK Inhibitor Dose TAPering Strategy Study\nEstimated primary completion:
  1 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upadac
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06687551
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05609630-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT05609630)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3.\nStudy: Study of Oral Upadacit
 inib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Diseas
 e Activity\, Adverse Events and How Drug Moves Through the Body of Pediatr
 ic and Adolescent Participants With Active Systemic Juvenile Idiopathic Ar
 thritis.\nEstimated primary completion: June 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05609630
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06461897-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06461897)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Atopic Dermatitis.\nStudy: A 
 Study to Assess Adverse Events and Change in Disease Activity Comparing Or
 al Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 
 12 Years of Age With Moderate to Severe Atopic Dermatitis\nEstimated prima
 ry completion: November 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/upadacitinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06461897
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700446-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT07700446)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4\, Ulcerative Colitis.\nStudy: E
 fficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative C
 olitis Who Lost Response to 30 mg Maintenance Dose\nEstimated primary comp
 letion: November 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/upadacitinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07700446
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258771-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT07258771)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4\, Ulcerative Colitis.\nStudy: U
 padacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy In
 duction for Inpatients and Outpatients With Acute Severe Ulcerative Coliti
 s\nEstimated primary completion: December 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07258771
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07588568-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Rinvoq (upadacitinib): Phase 2 readout est. (NCT07588568)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 2.\nStudy: A Trial of Upadacitini
 b for Non-responsive Eosinophilic Esophagitis\nEstimated primary completio
 n: February 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upa
 dacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07588568
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06012240-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06012240)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Alopecia Areata.\nStudy: A St
 udy to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Ad
 ult and Adolescent Participants With Severe Alopecia Areata\nEstimated pri
 mary completion: April 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/upadacitinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06012240
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Rinvoq (upadacitinib): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 4\, Atopic Dermatitis.\nStudy: Ut
 ilization of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated 
 primary completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07352566
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06332534-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06332534)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: Croh
 n's Disease: Efficacy\, Safety\, and Pharmacokinetics of Upadacitinib in P
 ediatric Subjects With Moderately to Severely Active Crohn's Disease\nEsti
 mated primary completion: January 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06332534
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772492-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT07772492)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Alopecia Areata.\nStudy: A St
 udy to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric 
 Participants With Alopecia Areata\nEstimated primary completion: March 203
 2. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07772492
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896434-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20320831
DTEND;VALUE=DATE:20320901
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT07896434)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Vitiligo.\nStudy: A Study to 
 Learn How Effective\, Safe\, and Tolerable Upadacitinib is for Young Parti
 cipants With Non-segmental Vitiligo\nEstimated primary completion: August 
 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078964
 34
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933211-12@assetmemo.bio
DTSTAMP:20261121T003112Z
DTSTART;VALUE=DATE:20350630
DTEND;VALUE=DATE:20350701
SUMMARY:Rinvoq (upadacitinib): Phase 2/3 readout est. (NCT07933211)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 2/3.\nStudy: A Study to Evaluate 
 the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 
 in Adult Participants With Systemic Sclerosis That Are Currently Receiving
  Local Standard of Care Treatment\, and to Determine the Best Dose of ABBV
 -2294 to be Evaluated Further.\nEstimated primary completion: June 2035. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07933211
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
